… Lung cancer is the leading cause of cancer mortality worldwide… Lung cancer, including all
histological subtypes, is more … As with lung cancer in general, SCLC is most prevalent in men …

… Various tumour-based and/or blood-based assays have been evaluated for their ability to
predict clinical benefit from immune-checkpoint inhibitors in patients with small-cell lung cancer…

… in the management of non-small cell lung cancer (NSCLC) with remarkable progresses in …
improved patient outcomes. This review will address updates in lung cancer screening, liquid …

… patients. Here we report an extensive molecular and immune profiling study of 245 … patients
with non-small cell lung cancer. Tumor-infiltrating lymphocyte estimated using immune cell …

… Lung cancer is the leading cause of cancer-related death worldwide with a high annual …
Non-small cell lung cancer (NSCLC) is the most common type of lung cancers, representing ~90…

… lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies
and immunotherapies for non-small-cell lung cancer … for clear-cut patient stratification, and …

… Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical,
and molecular characteristics from non–small-cell lung cancer. SCLC has high metastatic …

… in extensive disease small-cell lung cancer was performed in 2017. In this study, 30
patients in the expansion phase received treatment, and 20 patients reported over 1 treatment-…

… T cell clonality is associated with CD8 T cells To study the attributes of the T cell repertoire in
localized lung cancers, … 236 resected tumors from treatment-naïve NSCLC patients 16,17 . T …

… of elderly patients with non-small-cell lung cancer.  … B patients receiving low-dose CT scans
for lung cancer screening (… management of elderly patients with non-small-cell lung cancer.  …